Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

R-tech Ueno Completes Phase II For Ocuseva

This article was originally published in PharmAsia News

Executive Summary

Tokyo-based R-tech Ueno announced June 3 completion of a Phase II study for Ocuseva (UF-021) eye drops for retinitis pigmentosa, a rare disease expected to affect one in 5,000 people

Tokyo-based R-tech Ueno announced June 3 completion of a Phase II study for Ocuseva (UF-021) eye drops for retinitis pigmentosa, a rare disease expected to affect one in 5,000 people.

The randomized, double-blind study enrolled 112 patients with mid- and late-stage symptoms. The company said the drug shows improvement in visual function in both visual field tests and subjective findings. There are no major adverse effects except irritation upon administration. R-tech is analyzing the data and plans to release it at an academic conference. (Click here for more - Japanese language)

"R-Tech Ueno Shares Up Due To P-II Study For UF-021 Completion"--Search China News (6/4/2010)

Table

View full table

Tags:
Latest Headlines

Xaira Launches With $1bn-Plus And End-To-End AI Strategy

Biogen Sees Improving Momentum In Slow Leqembi Launch

Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative

Day One Springs Into Commercial Action With Ojemda Approval

See All
UsernamePublicRestriction

Register

SC075279

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By